Bristol Myers Squibb Co (NYSE:BMY) announced on Tuesday the first presentation of results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to lenvatinib or sorafenib for unresectable hepatocellular carcinoma (HCC). Related: FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies. With a median follow-up ...